Anti-Mouse Monoclonal Antibody to Human LAG3 (Clone: LG.F9)

LAG-3 (Lymphocyte activation gene-3), designated CD223, is a 70 kDa type I transmembrane protein that is a member of the immunoglobulin superfamily (IgSF). LAG-3 is expressed on activated CD4+ and CD8+ T cells, NK cells, and plasmacytoid dendritic cells (pDC), but not on resting T cells. LAG-3 on activated CD4+CD25+ Treg cells plays a role in their suppressive activity. LAG-3 limits the expansion of activated T cells and pDC in response to selected stimuli. In mice, deletion of LAG-3 and another negative regulator, PD-1, facilitates anti-cancer response but also blocks self-tolerance and increases susceptibility to autoimmune diseases. In humans, antibody-mediated down-regulation of LAG-3 and PD-1 allows more effective control of chronic malaria, while in NOD (non-obese diabetic) mice, deletion of LAG-3 alone accelerates diabetes. Human LAG3 Antibody (LG.F9), mAb, Mouse is produced from a hybridoma resulting from the fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Recombinant human LAG3-Fc. Protein function: Involved in lymphocyte activation. Binds to HLA class-II antigens. [The UniProt Consortium]